Dabrafenib, in combination with trametinib, is indicated for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.
|NCPE Assessment Process||Complete|
|Rapid Review commissioned||30/01/2019|
|Rapid Review completed||21/03/2019|
|Rapid Review Outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dabrafenib plus trametinib (Tafinlar® plus Mekinist®) compared with the current standard of care.